Ormone anti-mülleriano (AMH): utilità e limiti nella valutazione della riserva ovarica
- 33 Downloads
Anti-Müllerian hormone (AMH): utilities and criticisms in evaluation of ovarian reserve
The circulating anti-Müllerian Hormone (AMH) is considered a robust ovarian biomarker available today, inasmuch as, it has replaced the usage of age, antral follicle count (AFC) or follicle-stimulating hormone (FSH) levels. In this brief review, first we discuss its role during fetal and adult life in regulating follicle development. Subsequently, based on existing literature, we consider biological, preanalytical and analytical pitfalls and inherent biases in its assessment. Different generations of ELISA assays have been used since 1990s for AMH detection. However, more recently, rapid new automated methods with higher analytical sensitivity have been introduced. In view of this development, a major concern is to establish new reference and cutoff values based on these latest methods. Furthermore, the lack of an international standard makes the issue more complex. Our review, while asserting the pivotal role of AMH in the evaluation of ovarian reserve, suggests that more than one determination would be desirable before commencing the IVF treatment. Overall, automated methods have allowed to adopt AMH measurement as a routine test providing rapid access to results, thus contributing to better treatment options in centers for medically assisted reproduction.
KeywordsAnti-Müllerian hormone AMH Fertility treatment Follicle development Ovarian reserve
Conflitti di interesse
Studi condotti su esseri umani e animali
Per questo tipo di studio non è richiesto l’inserimento di alcuna dichiarazione relativa agli studi effettuati su esseri umani e animali.
- 7.National Collaborating Centre for Women’s and Children’s Health NICE (2013) Fertility: assessment and treatment for people with fertility problems. The Royal College of Obstetricians and Gynaecologists, London. https://www.nice.org.uk/guidance/cg156/evidence/full-guideline-pdf-188539453 (Accesso 25 settembre 2018)
- 8.Michael ABN (2017) Measurement of the Anti- Müllerian Hormone (AMH) in endocrinology: a mini-review. Invest Gynecol Res Women’s Health. https://www.healthconsultancynaafs.com/2017/10%20nov/IGRWH.000509%20AMH%20Published.pdf (Accesso 25 settembre 2018)
- 14.Plante BJ, Cooper GS, Baird DD et al. (2010) The impact of smoking on antimüllerian hormone levels in women aged 38 to 50 years. Menopause 17:571–576 Google Scholar
- 16.Tal R, Seifer DB (2013) Potential mechanisms for racial and ethnic differences in antimüllerian hormone and ovarian reserve. Int J Endocrinol 818912 Google Scholar
- 18.Long WQ, Ranchin V, Pautier P et al. (2000) Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 85:540–544 Google Scholar
- 19.Groome NP, Cranfield M, Themmen A et al (2011) Immunological assay and antibodies for anti-müllerian hormone. Patent application filed 24th May 2006. Patent granted March Ist 2011 Immunological assay and antibodies for anti-Müllerian hormone. US Patent 7, 897, 350 B2. https://patentimages.storage.googleapis.com/a2/64/9c/5b602e9774d5c7/US7897350.pdf (Accesso 25 settembre 2018)